Skip to main content
. 2018 Dec 31;8(1):e009122. doi: 10.1161/JAHA.118.009122

Figure 2.

Figure 2

Cumulative incidence of heart failure (grades 3, 4, and 5) for 2 specific treatment groups: anthracyclines only (n=2598 cohort members, 96 cases) and mitoxantrone (with/without anthracyclines) (n=146 cohort members, 12 cases). All childhood cancer survivors who had radiotherapy involving the heart region were excluded from these analyses. Parwise comparisons found these degrees of significance: no anthracycline/mitoxantrone vs anthracycline 1 to 100 mg/m2, P=0.17; no anthracycline/mitoxantrone vs anthracycline 100 to 250 mg/m2, P<0.00001; no anthracycline/mitoxantrone vs anthracycline >250 mg/m2, P<0.00001; no anthracycline/mitoxantrone vs mitoxantrone, P<0.00001; anthracycline 1 to 100 mg/m2 vs anthracycline 100 to 250 mg/m2, P=0.007; anthracycline 1 to 100 mg/m2 vs anthracycline >250 mg/m2, P<0.00001; anthracycline 1 to 100 mg/m2 vs mitoxantrone, P<0.00001; anthracycline 100 to 250 mg/m2 vs anthracycline >250 mg/m2, P<0.00001; anthracycline 100 to 250 mg/m2 vs mitoxantrone, P<0.00001; anthracycline >250 mg/m2 vs mitoxantrone, P=0.02. Shaded areas indicate 95% CI.